Should Patients Be Required to Undergo Standard Chemotherapy Before Being Eligible for Novel Phase I Immunotherapy Clinical Trials?

Benjamin S. Wilfond; Christian Morales; Holly A. Taylor

doi:10.1080/15265161.2017.1284934

Should Patients Be Required to Undergo Standard Chemotherapy Before Being Eligible for Novel Phase I Immunotherapy Clinical Trials?

Benjamin S. Wilfond, Christian Morales, Holly A. Taylor

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	66-67
Number of pages	2
Journal	American Journal of Bioethics
Volume	17
Issue number	4
DOIs	https://doi.org/10.1080/15265161.2017.1284934
State	Published - Apr 3 2017

ASJC Scopus subject areas

Health Policy
Issues, ethics and legal aspects

Access to Document

10.1080/15265161.2017.1284934

Cite this

@article{55f6189fa2444315bdadf5f74c4aee61,

title = "Should Patients Be Required to Undergo Standard Chemotherapy Before Being Eligible for Novel Phase I Immunotherapy Clinical Trials?",

author = "Wilfond, {Benjamin S.} and Christian Morales and Taylor, {Holly A.}",

year = "2017",

month = apr,

day = "3",

doi = "10.1080/15265161.2017.1284934",

language = "English (US)",

volume = "17",

pages = "66--67",

journal = "American Journal of Bioethics",

issn = "1526-5161",